10x Genomics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-255.1	-166	-58.22	-542.73	-31.25	-112.49	-18.76
Depreciation & Amortization	43.62	33.01	28.25	19.02	7.07	3.91	4.31
Share-Based Compensation	166.95	136.85	95.96	48.63	13.33	2.66	1.66
Other Operating Activities	29.33	-37.46	-87.37	257.19	45.48	29.51	2.1
Operating Cash Flow	-15.2	-33.61	-21.37	-217.9	34.63	-76.41	-10.7
Capital Expenditures	-48.6	-131.66	-101.28	-36.67	-42.74	-6.28	-3.76
Acquisitions	0	-4	-5.45	0	0	0	0
Change in Investments	183.02	-215.23	0	0	0	0	0
Other Investing Activities	-0.92	-	-	-1.73	-0.03	-0.43	-
Investing Cash Flow	133.49	-350.89	-106.73	-38.39	-42.77	-6.71	-3.76
Share Issuance / Repurchase	19.48	21.23	40.33	506.01	414.59	1.8	1.01
Debt Issued / Paid	0	0	0	-31.26	0	18.74	-0.39
Other Financing Activities	-5.81	-5.41	-5.03	-5.85	-	84.83	19.96
Financing Cash Flow	13.67	15.82	35.3	468.91	414.59	105.37	20.58
Exchange Rate Effect	-0.03	-0.04	0.23	-0.46	-0.05	-0.02	-0.01
Net Cash Flow	131.93	-368.72	-92.57	212.15	406.41	22.23	6.11
Free Cash Flow	-63.8	-165.27	-122.65	-254.56	-8.12	-82.69	-14.46
Free Cash Flow Margin	-10.31%	-32.00%	-25.01%	-85.18%	-3.30%	-56.52%	-20.33%
Free Cash Flow Per Share	-0.55	-1.45	-1.11	-2.52	-0.21	-6.17	-1.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).